Virological determinants of drug resistance in real-world patients with chronic HCV infection [ 2014 - 2016 ]

Research Grant

Researchers: Prof Alexander Thompson (Principal investigator) ,  A/Pr Fabio Luciani ,  A/Pr Gail Matthews ,  A/Pr Michael Beard ,  Dr Amanda Aloia
View all 6 related researchers

Brief description New treatments for hepatitis C virus (HCV) infection are emerging. These drugs directly target key events in the viral life cycle. While these drugs are effective, the ability of HCV to mutate means that drug resistance can arise, leading to treatment failure. This is most likely in patients who do not respond to interferon-based therapy. This proposal will use new, highly sensitive sequencing approaches to identify the viral mutations and evolutionary pathways that lead to drug resistance.

Funding Amount $AUD 550,718.01

Funding Scheme Project Grants

Notes Standard Project Grant